XML 51 R33.htm IDEA: XBRL DOCUMENT v3.25.1
REVENUES (Tables)
12 Months Ended
Dec. 31, 2024
Revenue from Contract with Customer [Abstract]  
SCHEDULE OF ACCRUALS AND ALLOWANCES

The following table summarizes activity and ending balances of the Company’s variable consideration provisions in the consolidated financial statements for the years ended December 31, 2024, and 2023:

 

SCHEDULE OF ACCRUALS AND ALLOWANCES

   Chargebacks   Government Rebates   Returns   Administrative Fees and Other Rebates     Co-Pay Assistance       Prompt Pay Discounts       Total 
   Accruals for Chargebacks, Returns, and Other Allowances  
   Chargebacks   Government Rebates   Returns   Administrative Fees and Other Rebates   Co-Pay Assistance     Prompt Pay Discounts     Total 
Balance at December 31, 2022 (1)   256,000    -    49,000    370,000     -      31,000       706,000 
Accruals/Adjustments   6,093,000    5,153,000    1,576,000    33,498,000     1,310,000      1,542,000       49,172,000 
Credits Taken Against Reserve   (3,539,000)   (1,568,000)   (854,000)   (9,799,000)    (339,000 )    (472,000 )     (16,571,000)
Balance at December 31, 2023 (1)   2,810,000    3,585,000    771,000    24,069,000     971,000    1,101,000       33,307,000 
Accruals/Adjustments   8,607,000    11,968,000    9,089,000    81,722,000     98,052,000      5,941,000       215,379,000 
Credits Taken Against Reserve   (10,457,000)   (3,193,000)   (8,411,000)   (72,918,000)    (89,411,000 )    (4,665,000 )     (189,055,000)
Balance at December 31, 2024 (1)   960,000    12,360,000    1,449,000    32,873,000     9,612,000      2,377,000       59,631,000 

 

(1)Chargebacks and other allowances are included as an offset to accounts receivable in the consolidated balance sheets. Administrative Fees and Other Rebates, Prompt Payment Discounts and Returns are included as a reduction to accounts receivable, net of chargebacks and other allowances or accrued expenses and other in the consolidated balance sheets. Government Rebates are included in accrued government rebates and copay assistance in the consolidated balance sheets.
SCHEDULE OF DISAGGREGATED REVENUE

Revenue disaggregated by revenue source for the years ended December 31, 2024 and 2023, consists of the following:

   

   2024   2023 
   For the Years Ended December 31, 
   2024   2023 
Product sales, net  $198,619,000   $117,447,000 
Transfer of acquired product sales/profits   995,000    12,746,000 
Total revenues  $199,614,000   $130,193,000